Pharmaceutical Industry in China - An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges” provides you with a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 196 tables & figures within 142 pages. The Chinese biopharmaceutical market is presented as follows:
By Company (e.g., AMOYTOP BIOTECH, BEIJING CONTINENT PHARMACEUTICALS, FUSOGEN, SHANGHAI HUAGUAN BIOCHIP, SIBIONO GENETECH, ABBOTT, ROCHE, PFIZER, GSK, NOVARTIS)
By Therapeutic Area (e.g., Anti-infective, Cancer, Diabetes, Dementia, Depression)
A wealth of financial information is provided including:
Company financials, sales & revenue figures historical to Q2 2013
China GDP, economic growth, export (bulk drug, formulations) figures
Indian health expenditure as a function of GDP
Growth change figures of emerging and developing countries (India, Russia, China, Brazil)
Economic growth figures of advanced economies (USA, UK, Germany, France, Italy, Spain, Japan, Canada)
Projected figures of strategic emerging industry GDP percentage contribution
SWOT, Economic and Business Environment specifics include:
Key strengths, weaknesses and threats influencing leading player position within the market
Top Five Contract Pharmaceutical Export Markets of China
Major players within China’s leading therapeutic markets (e.g., cancer, allergy, liver disease)
Multinational penetration into the Chinese Pharma Market
Comprehensive product portfolios, R&D activity and pipeline therapeutics
M&A activity and future strategies of top Chinese pharmacos
Economic indicators, trade policy, merchandise and commercial trade statistics
Gross Domestic Product of China, historic and projection analysis
Chinese economic outlook in comparison to advanced economies
Three Tier ‘Pharmerging’ Markets with Potential for Significant Growth
Prescription drug sales distribution channels in China
Major biogeneric products in China
This report highlights a number of significant Chinese and multinational pharmacos and gives details of their operations, products, financials and business strategy.
Amoytop Biotech
Active Pharmaceutical Products
Beijing Continent Pharmaceuticals
FusoGen Pharmaceuticals
Shanghai Huaguan Biochip
SiBiono GeneTech
Abbott
AstraZeneca
Boehringer Ingelheim
Eli Lilly
GlaxoSmithKline
Johnson & Johnson Medical
Merck
Novartis
Pfizer
Roche
Forecast projections and future growth rates are provided to give you a forthcoming perspective of this growing industry. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.
